KRAS and neoplasm: In addition, IT CXCL9/10-DC enhances the relatively modest efficacy of PD-1/PD-L1 blockade in a Lkb1-deficient, Kras-mutant murine NSCLC model with high TMB, leading to the complete eradication of a subset of tumors and the establishment of tumor-specific immune memory.